Key Performance
More- Earnings Score: N/A
- Momentum Score: 23
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly inspect or audit the vendor's facility, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate product. Investors who purchased securities between December 29, 2025 and June 29, 2026 are encouraged to join the case.
11/02/2026, 10:00 AM • GlobeNewswire
A class action lawsuit has been filed against Unicycive Therapeutics for allegedly making false and misleading statements regarding its third-party manufacturing vendor. The company allegedly failed to inspect the vendor's facility or audit compliance with manufacturing practices, creating undisclosed risks of FDA delays for oxylanthanum carbonate approval. Investors who purchased shares between December 29, 2025 and June 29, 2026 have until November 2, 2026 to apply as lead plaintiff.
10/31/2026, 9:06 AM • GlobeNewswire
A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly audit the vendor's facility and lacked reasonable basis for believing deficiencies were remedied, creating material risk of regulatory delays for oxylanthanum carbonate approval. Investors who purchased securities between December 29, 2025 and June 29, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 2, 2026.
10/29/2026, 10:00 AM • GlobeNewswire
Rosen Law Firm issued deadline notices for securities class action lawsuits against Unicycive Therapeutics (UNCY), York Space Systems (YSS), and Papa John's International (PZZA). The UNCY lawsuit alleges the company made false statements about manufacturing compliance and FDA approval prospects for its oxylanthanum carbonate drug. Investors have until specified deadlines in late October and early November 2026 to join the class actions.
10/24/2026, 7:02 PM • GlobeNewswire
A class action lawsuit has been filed against Unicycive Therapeutics for alleged securities fraud. The complaint alleges that the company made false statements about its manufacturing vendor's FDA compliance and failed to disclose material risks regarding regulatory approval delays for oxylanthanum carbonate. Investors who purchased shares between December 29, 2025 and June 29, 2026 may be eligible to join the lawsuit.
10/22/2026, 10:00 AM • GlobeNewswire
Rosen Law Firm reminds investors of Unicycive Therapeutics who purchased securities between December 29, 2025 and June 29, 2026 of the November 2, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Unicycive made materially false statements regarding its third-party manufacturing vendor's FDA compliance and failed to disclose risks of regulatory delays for its oxylanthanum carbonate drug candidate.
10/21/2026, 5:32 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp. (AVXL) for allegedly making false statements about internal controls and regulatory challenges related to former CEO misconduct. Similar lawsuits have been filed against AppLovin Corporation (APP) and Unicycive Therapeutics, Inc. (UNCY). Investors have until November 30, 2026 to become lead plaintiffs.
10/18/2026, 3:04 PM • GlobeNewswire
Rosen Law Firm is notifying investors about securities class action lawsuits, including one against Unicycive Therapeutics for allegedly making false statements about its manufacturing vendor's FDA compliance and the regulatory approval timeline for its drug oxylanthanum carbonate. The lead plaintiff deadline is November 2, 2026. Similar lawsuits have been filed against Webull Corporation and Alphabet Inc.
10/18/2026, 11:38 AM • GlobeNewswire
Robbins LLP reminds investors of a class action lawsuit against Unicycive Therapeutics (UNCY) for allegedly failing to disclose that it had not inspected its third-party manufacturing vendor's facility to ensure FDA deficiencies were resolved. The FDA issued a Complete Response Letter in June 2026 citing the same manufacturing deficiencies as a previous CRL, causing UNCY stock to drop 39.1% to $4.69 per share. The class period covers purchases between December 29, 2025 and June 29, 2026, with a lead plaintiff deadline of November 2, 2026.
10/14/2026, 7:31 PM • GlobeNewswire
Unicycive Therapeutics (UNCY) shareholders are urged to file claims in a securities fraud class action lawsuit. The company's stock fell 39.1% on June 30, 2026, after the FDA issued a Complete Response Letter citing the same third-party manufacturing deficiencies as a previous rejection. The lawsuit alleges defendants made false statements and failed to disclose that the company had not properly audited its manufacturing vendor's compliance with FDA standards.
10/14/2026, 2:40 PM • GlobeNewswire
Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics securities between December 29, 2025 and June 29, 2026 about the November 2, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Unicycive made materially false statements regarding its third-party manufacturing vendor's FDA compliance and failed to disclose risks of regulatory delays for its oxylanthanum carbonate drug candidate.
10/11/2026, 7:27 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026.
10/06/2026, 7:00 AM • GlobeNewswire
A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. (UNCY) for allegedly making materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims the company failed to disclose that it had not inspected the vendor's facility or audited its compliance with manufacturing practices, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate drug. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.
10/05/2026, 9:24 PM • GlobeNewswire
Unicycive Therapeutics faces a securities fraud class action lawsuit after the FDA issued a Complete Response Letter (CRL) on June 30, 2026, citing the same third-party manufacturing deficiencies as a previous rejection. The stock fell 39.1% on the news. The lawsuit alleges the company failed to disclose that it had not inspected its manufacturing vendor's facility or audited compliance with manufacturing practices, and lacked reasonable basis to believe deficiencies were resolved. The deadline to file a lead plaintiff motion is November 2, 2026.
10/05/2026, 2:50 PM • GlobeNewswire
A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly audit the vendor's facility and lacked reasonable basis for positive statements about regulatory approval prospects for oxylanthanum carbonate. Investors who purchased securities between December 29, 2025 and June 29, 2026 may be eligible to join the case.
10/05/2026, 12:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 11/10/2026
Company Profile
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.